Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.780
+0.020 (1.14%)
At close: Dec 20, 2024, 4:00 PM
1.850
+0.070 (3.93%)
After-hours: Dec 20, 2024, 6:37 PM EST
Quince Therapeutics Employees
Quince Therapeutics had 32 employees as of December 31, 2023. The number of employees increased by 11 or 52.38% compared to the previous year.
Employees
32
Change (1Y)
11
Growth (1Y)
52.38%
Revenue / Employee
n/a
Profits / Employee
-$1,664,500
Market Cap
78.32M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
I-Mab | 220 |
Rani Therapeutics Holdings | 140 |
Theratechnologies | 103 |
ALX Oncology Holdings | 72 |
InspireMD | 66 |
PMV Pharmaceuticals | 63 |
Ikena Oncology | 43 |
Genelux | 23 |
QNCX News
- 5 weeks ago - Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire
- 5 weeks ago - Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research - Business Wire
- 5 weeks ago - Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting - Business Wire
- 2 months ago - Quince Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
- 3 months ago - Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
- 4 months ago - Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex - Seeking Alpha
- 4 months ago - Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T) - Business Wire
- 4 months ago - Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results - Business Wire